"It's criminal to put someone on a GLP-1 and not put them on a dietary plan," says Phil Vella, founder of Vita Bella Health, ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...

Detailed Phase IIIb STEP UP trial results presented at the 2025 ADA Scientific Sessions found that an investigational 7.2 mg dose of Wegovy (semaglutide) led to a mean weight loss of 21% in adults ...

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with or without type 2 diabetes, a pair of phase IIIa trials found.

In a Cleveland Clinic cohort, patients who stopped treatment for obesity had smaller weight losses to start, making these ...

Efficacy and safety of semaglutide 7.2 mg in obesity and type 2 diabetes: STEP UP T2D trial. Poster presentation (1978-LB poster) - Sunday 22 June; 12:30–13:30 CDT CagriSema ...

VANCOUVER, BC / ACCESS Newswire / June 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT), is pleased to announce the launch of a feasibility study for the ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Below are a few more promising studies of weight-loss drugs. Combining bimagrumab, an investigational human monoclonal ...

Novo Nordisk to present data from STEP UP trial on a higher dose of Wegovy® (semaglutide 7.2 mg) for those in need of greater weight loss Data will expand semaglutide evidence in both a clinical ...